Mini-review: Discovery and development of platinum complexes designed to circumvent cisplatin resistance

Journal of Inorganic Biochemistry

Volumn 77, Issue 1-2, 1999, Pages 111-115

  Kelland, Lloyd R ^a   Sharp, Swee Y ^a   O'Neill, Ciaran F ^a   Raynaud, Florence I ^a   Beale, Philip J ^a   Judson, Ian R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Circumvention; Platinum drugs; Resistance

Indexed keywords

AMMINEBISBUTYRATODICHLORO(CYCLOHEXYLAMINE)PLATINUM; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTINEOPLASTIC AGENT; CARBOPLATIN; CIS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM; CISPLATIN; GLUTATHIONE; IPROPLATIN; PACLITAXEL; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; PLATINUM COMPLEX; PROTEIN BCL 2; SATRAPLATIN; THIOL DERIVATIVE; TRANS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; DRUG RESEARCH; DRUG RESISTANCE; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0033389391     PISSN: 01620134     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-0134(99)00141-5     Document Type: Article

References (29)

1. Adams M., Calvert A.H., Carmichael J., Clark P.L., Coleman R.E., Earl H.M., Gallagher C.J., Ganesan T.S., Gore M.E., Graham J.D., Harper P.G., Jayson G.C., Kaye S.B., Ledermann J.A., Osborne R.J., Perren T.J., Poole C.J., Radford J.A., Rustin G.J.S., Slevin M.L., Smyth J.F., Thomas H., Wilkinson P.M. Br. J. Cancer. 78:1998;1404-1406.
2. Connors T.A., Cleare M.J., Harrap K.R. Cancer Treat. Rep. 63:1979;1499-1502.
3. Harrap K.R. Cancer Treat. Rev. 12:1985;21-33.
4. Kelland L.R. Crit. Rev. Oncol/Hematol. 15:1993;191-219.
5. Kelland L.R., Jones M., Gwynne J.J., Valenti M., Murrer B.A., Barnard C.F.J., Vollano J.F., Giandomenico C.M., Abrams M.J., Harrap K.R. Int. J. Oncol. 2:1993;1043-1048.
6. Kelland L.R., Murrer B.A., Abel G., Giandomenico C.M., Mistry P., Harrap K.R. Cancer Res. 52:1992;822-828.
7. Kelland L.R., Abel G., McKeage M.J., Jones M., Goddard P.M., Valenti M., Murrer B.A., Harrap K.R. Cancer Res. 53:1993;2581-2586.
8. McKeage M.J., Raynaud F., Ward J., Berry C., Odell D., Kelland L.R., Murrer B., Santabarbara P., Harrap K.R., Judson I.R. J. Clin. Oncol. 15:1997;2691-2700.
9. Johnson S.W., Ferry K.V., Hamilton T.C. Drug Resistance Updates. 1:1998;243-254.
10. Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P., Harrap K.R. Br. J. Cancer. 59:1989;527-534.
11. Kelland L.R., Mistry P., Abel G., Loh S.Y., O'Neill C.F., Murrer B.A., Harrap K.R. Cancer Res. 52:1992;3857-3864.
12. Harrap K.R., Jones M., Siracky J., Pollard L., Kelland L.R. Ann. Oncol. 1:1990;65-76.
13. Kelland L.R., Jones M., Abel G., Valenti M., Gwynne J.J., Harrap K.R. Cancer Chemother. Pharmacol. 30:1992;43-50.
14. Jones M., Siracky J., Kelland L.R., Harrap K.R. Br. J. Cancer. 67:1993;24-29.
15. Kelland L.R., Barnard C.F.J., Mellish K.J., Jones M., Goddard P.M., Valenti M., Bryant A., Murrer B.A., Harrap K.R. Cancer Res. 54:1994;5618-5622.
16. Farrell N., Kelland L.R., Roberts J.D., Beusichem M.V. Cancer Res. 52:1992;5065-5072.
17. Collucia M., Nassi A., Loseto F., Boccarelli A., Mariggio M.A., Giordano D., Intini F.P., Caputo P., Natile G.A. J. Med. Chem. 36:1993;510-512.
18. Kelland L.R., Barnard C.F.J., Evans I.G., Murrer B.A., Theobald B.R.C., Wyer S.B., Goddard P.M., Jones M., Valenti M., Bryant A., Rogers P.M., Harrap K.R. J. Med. Chem. 38:1995;3016-3024.
19. Goddard P.M., Orr R.M., Valenti M.R., Barnard C.F.J., Murrer B.A., Kelland L.R., Harrap K.R. Anticancer Res. 16:1996;33-38.
20. Mellish K.J., Barnard C.F.J., Murrer B.A., Kelland L.R. Int. J. Cancer. 62:1995;717-723.
21. O'Neill C.F., Ormerod M.G., Robertson D., Titley J.C., Cumber-Walseer Y., Kelland L.R. Br. J. Cancer. 74:1996;1037-1045.
22. Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R. Br. J. Cancer. 64:1991;215-220.
23. Holford J., Raynaud F., Murrer B.A., Grimaldi K., Hartley J.A., Abrams M., Kelland L.R. Anti-cancer Drug Des. 13:1998;1-18.
24. Holford J., Sharp S.Y., Murrer B.A., Abrams M., Kelland L.R. Br. J. Cancer. 77:1998;366-373.
25. Raynaud F.I., Boxall F.E., Goddard P.M., Valenti M., Jones M., Murrer B.A., Abrams M., Kelland L.R. Clin. Cancer Res. 3:1997;2063-2074.
26. Kelland L.R., Barnard C.F.J. Drugs Future. 23:1998;1062-1065.
27. Aebi S., Fink D., Gordon R., Kim H.K., Zheng H., Fink J.L., Howell S.B. Clin. Cancer Res. 3:1997;1763-1767.
28. J.C. Reed, in: S.J. Martin (Ed.), Apoptosis and Cancer, BCL-2 Family Proteins: Role in Dysregulation of Apoptosis and Chemoresistance in Cancer, Karger-Landes Systems, Basle, 1997, pp. 64-97.
29. Mistry P., Loh S.Y., Kelland L.R., Harrap K.R. Int. J. Cancer. 55:1993;848-856.